Sign in
Taking people in United StatesNo phase

Blood test-guided clot prevention after leg artery procedures in peripheral artery disease

Tests a blood test-tailored clot prevention plan in adults with peripheral artery disease.

Key facts

Who runs it
Massachusetts General Hospital
Where
Boston and Salem, United StatesSee the 2 sites
Trial code
Registry title
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
Status
Recruiting
People taking part
484 people, planned
Started
29 Apr 2025
Expected to end
30 Jun 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Aspirin
  • Clopidogrel
  • Ticagrelor
  • Rivaroxaban
  • Thromboelastography with Platelet Mapping
Record updated
11 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with peripheral artery disease or a limb artery injury who need a procedure to restore blood flow in an artery. It compares blood-test-guided clot prevention medicine with standard treatment.

Age
18 years or older
Sex
All sexes
Disease stage
An injury to a named artery of an arm or leg, or a named blood vessel that needs reopening because of atherosclerosis (fatty build-up in the arteries). The reopening can be open surgery, a closed procedure through the vessel, or both.

Main reasons for not taking part

  • Known pregnancy
  • No atherosclerosis
  • Active stomach ulcers
  • Severe liver problems
  • Recent bleeding inside the skull. Prisoners admitted directly from a correctional facility also cannot join.

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Patients with a named arterial extremity injury or named vessel revascularization for atherosclerosis requiring open and/or closed revascularization
  • Patients at the age of 18 or older

Who cannot take part

  • Known pregnancy (females of childbearing potential will have a pregnancy test prior to surgery as per standard of care)
  • Subject has severe hepatic impairment
  • Subject has a recent history of intracranial hemorrhage. If the patient has a history of cerebral hemorrhage with no new central nervous system disease of >1 year, the study team will consult with the
  • Patients who are younger than 18 years old
  • Prisoners, defined as those who have been directly admitted from a correctional facility
  • No atherosclerosis
  • Subject has active stomach ulcers

Where in United States

  • Massachusetts General HospitalBoston, United StatesContact: Anahita Dua, MBCHB, MBA, MSCTaking people
  • Salem Hospital (Mass General Brigham)Salem, United StatesContact: Shaidah Deghan, MD, MSCTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to determine whether a personalised blood clot prevention plan is more effective than standard treatment in adults with peripheral artery disease (PAD) who have undergone a procedure to restore blood flow to their legs.

Read full original descriptionShow less

The main questions it aims to answer are:

* Does the personalized plan lower the rate of blood clots in the treated leg one year after the procedure? * Does the personalized plan lower rates of amputation, repeat procedures, bleeding, and death compared to standard treatment?

Researchers will compare the personalized TARGET plan which uses a blood test to tailor each person's blood clot prevention medication to the standard treatment to see if the personalized approach works better.

Participants will:

* Be randomly assigned to either the personalized TARGET plan or standard treatment after their procedure * Have blood tests at 1 week and at 1, 3, 6, 9, and 12 months after their procedure * Have medications adjusted based on blood test results if assigned to the TARGET group

The 2 groups in the trial

  • TARGETTreatment being tested

    Participants receive postoperative antiplatelet therapy consistent with standard of care, with regimen adjustments guided by serial TEG-PM (Thromboelastography with Platelet Mapping) assessments. The goal is to maintain platelet inhibition within a therapeutic window of 29-86%. If platelet inhibition falls outside this range at any timepoint, the antiplatelet regimen is escalated or de-escalated per a prespecified algorithm. TEG-PM testing occurs at 1 week, 1, 3, 6, 9, and 12 months postoperatively, with repeat testing 7 days after any medication change.

    Treatment: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, and Thromboelastography with Platelet Mapping

  • Standard of Care (SOC)Existing treatment, for comparison

    Participants receive standard postoperative antiplatelet therapy per the treating surgeon's preference (dual antiplatelet therapy or aspirin combined with low-dose rivaroxaban) for the 12-month follow-up period. TEG-PM testing is performed at all scheduled timepoints for data collection purposes only; no medication adjustments are made based on results.

    Treatment: Aspirin, Clopidogrel, Ticagrelor, Rivaroxaban, and Thromboelastography with Platelet Mapping

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Personalizing Post Surgical Thromboprophylaxis for Patients With Peripheral Artery Disease
Plain-language title
Blood test-guided clot prevention after leg artery procedures in peripheral artery diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
11 September 2026